Letter to the Editor
Response to “an innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)”
Abstract
We thank Drs. Viteri and Rosell for their thoughtful comments on our paper “Safety and activity of microRNAloaded mini-cells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study” published in the October 2017 issue of Lancet Oncology (1).
